Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge

Table 3 Studies assessing the prognosis of the signet-ring cell histotype in advanced gastric cancer

Ref.	Number of patients in study	Number of advanced gastric cancers	SRCC frequency in advanced gastric cancer	Median 5-yr survival of SRCC (vs non-SRCC)	P-value
Maehera et al[57] (1992)	1500	1116	2%	48% (vs 33%)	NS
Kim et al[53] (1994)	3702	NP	NP	32% (vs 45%)	< 0.05
Otsuji et al[58] (1998)	1498	630	9.5%	44% (vs 28%)	NS
Yokota et al[56] (1998)	923	NP	NP	11% (vs 38%)	NS
Theuer et al[59] (1999)	3020	NP	NP	NP	NS (multivariate)
Kim et al[45] (2004)	2358	1797	6%	35% (vs 40%)	NS
Kunisaki et al[43] (2004)	1113	600	9%	NP	NS
Li et al[42] (2007)	4759	4759	14%	42% (vs 51%)	0.009
Messager et al[68] (2011)	159	NP	NP	9% (vs 24%)	0.038
Taghavi et al[3] (2013)	12246	6261	26.3%	NP	NS (multivariate)
Jiang et al[44] (2011)	2315	2046	7%	31.5% (vs 35.7%)	NS
Kwon et al[11] (2014)	769	443	12.8%	26% vs 50.5%1	0.004
Zu et al[14] (2014)	741	741	5.9%	43.4% vs 87.1%2	0.0123
Heger et al[55] (2014)	723	312	33.5%	NP	0.02 (multivariate)

¹Ten-year survival;

²vs well-differentiated cancer;

³Comparison between all histotypes (well differentiated, moderately differentiated, poorly differentiated and SRCC). SRCC: Signet-ring cell carcinoma.